Navigation Links
Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
Date:9/4/2007

Sources Cite China as Having the Highest Mortality Rate of Asthma in the

World, and Decision Resources Finds Low Diagnosis Rates and Low

Drug-Treatment Rates as a Possible Rationale

WALTHAM, Mass., Sept. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the asthma drug market in China will experience dramatic growth, due to an expanding prevalent population. According to the new Emerging Markets report entitled Asthma in China, the diagnosed asthma population will increase 57 percent in the next five years. An expanding population will be the key driver of this dramatic growth, but increases in the uptake of more expensive drugs, such as the combination product Seretide from GlaxoSmithKline, advocacy and promotion by the Chinese Asthma Alliance (a coordinated effort that promotes asthma prevention and treatment, improved physician education, and initiation of asthma studies), and an expanding middle class will affect the expanding drug market as well.

The report also finds that currently, there are significant barriers to diagnosis, such as the lack of disease awareness, difficulty establishing a differential diagnosis from other respiratory diseases, prohibitive cost of medical attention, lack of diagnostic technology, difficulty discerning variable symptoms (especially in a wheezing child), and the social stigma of asthma (individuals are embarrassed by not being able to breathe and therefore do not seek treatment for their symptoms). Chinese physicians also struggle with low compliance rates among their patients, further constraining optimal drug sales.

"Although the current asthma diagnosis and drug-treatment rates in China are low, the China Asthma Alliance is making strides in implementing new practices to better identify and treat patients," said Vickie Lai, analyst at Decision Resources. "This change pr
'/>"/>

SOURCE Decision Resources
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Obesity And Expanding Waistlines the next Epidemic in USA
2. Art of Living concept expanding around the globe
3. Expanding Price Control Detrimental for Pharma Companies: CII
4. Expanding waistlines: Only a tip of the iceberg?
5. AIDS More Prevalent Among Teenage Girls In The US
6. Fatigue, Prevalent Among Patients Treated For Breast Cancer
7. New PPUD Syndrome Prevalent Among Indian Doctors In Britain
8. Intermittent Explosive Disorder is More Prevalent Now Than Before
9. Aids Seems More Prevalent Among Goan’s – Governor Visiond
10. Prevalent Prescription Drugs Abuse in the US
11. Researchers Warn That Whooping Cough Is Still Very Prevalent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...h Annual Physician On-Call Pay .../ -- Sullivan, Cotter and Associates, Inc.,has pub...ll pay rates and,practices, the 2008 Physician On-...ta from 132 healthcare organizations nationwide, o...paid for 33 physician specialty areas along,with d...
(Date:7/25/2008)...lusivity Begins -, CORONA, Calif., July 25 /PRNew...NYSE: WPI ), a leading specialty pharmaceutical,c...mmenced commercial,shipment of its Omeprazole Dela...gth from its Davie, Florida manufacturing facility...ays of marketing exclusivity for being the,first t...
(Date:7/25/2008)...ert J. Reilly, Joins Aethon Team, PITTSBURGH, Jul...on.com ), the leading developer of mobile robotics...ced that Robert J. Reilly has,joined the company a...., Reilly, who was most recently Vice President -...alty Pharmacy Division, brings more than 30,years ...
(Date:7/25/2008)...ekta Family of Companies will,showcase their uniqu...merican Association of Physicists in Medicine (AAP...ces of Elekta, IMPAC and CMS are delivering,cuttin...utions that,streamline the treatment process to cr...enhance clinician efficiency., "Our recent acquis...
Breaking Medicine News(10 mins):Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3
...chers have discovered that a recently identified g...ighly aggressive form of the disease. These find...le blood test to predict who is susceptible to thi...esearchers said. Knowing which patients carry this...
...oped software that transforms a cellphone into a s...g lightning strike. A lightning bolt is an elect... producing frequencies between 10 hertz and five g...istribution of these signals depends on how far aw...
...oxic substance, made by certain types of bacteria ...ping the allergic skin condition eczema or wheezi... of 3. The toxic substance, Endotoxin is an eleme... bacteria, a type of bacteria that repeatedly caus...
..."Pound-for-Pound, The Most Powerful Weight-Loss Fo... screaming advertisements are common in many parts...e Canadians fall for them. But the concern is that... few regulations to govern this booming industry i...
Other Medicine News:Health News:Genetic Marker Linked to Aggressive Prostate Cancer 2Health News:Beware Weight Loss Drugs, Say Canadian Experts 2Health News:Beware Weight Loss Drugs, Say Canadian Experts 3Health News:Beware Weight Loss Drugs, Say Canadian Experts 4
(Date:7/24/2008)...y 24 /- Ortho-McNeil Neurologics, a,d...nc., announced today,that the U.S. Food and Drug A...ity for TOPAMAX(R) (topiramate), based on studies ...FDA to investigate the use of TOPAMAX,in pediatric...eizures., In addition to granting pediatric exclu...
(Date:7/24/2008)..., July 24 /- Alexza,Pharmac...at it has initiated,its second Phase 3 clinical tr...an inhalation product candidate being developed fo...h schizophrenia or bipolar disorder.,Alexza believ...cokinetic,(PK) properties resulting from inhaled l...
(Date:7/24/2008)...PRNewswire-USNewswire/ -- Headlines claiming "soy,...story. The small scale,preliminary study that Dr....ction, is based on recollected intake of soyfoods ...is study is confounded by many,issues, thus I feel...,caution," warned Dr. Tammy Hedlund, a researcher ...
(Date:7/24/2008)...eter designed to take body temperature, for home,a...e-FirstCall/ --- Kidz-Med, Inc.,(subsidiary of Ame...,United States distributor of the Thermofocus(R) ...unce the results of a clinical study,conducted by ...Milan, in,Milan, Italy, which proves that the Ther...
Breaking Medicine Technology:FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 2FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 6Soyfoods Do Not Impact Sperm Count 2Pediatric Study Finds 21st Century Non-Contact Thermometer as Accurate as Conventional Thermometers 2The Stay Strong Foundation Launches National Healing Starts With US Campaign With Celebrity Guests Denzel Washington Ruby Dee MoNique Terry McMilla 14367 1The Stay Strong Foundation Launches National Healing Starts With US Campaign With Celebrity Guests Denzel Washington Ruby Dee MoNique Terry McMilla 14367 2The Stay Strong Foundation Launches National Healing Starts With US Campaign With Celebrity Guests Denzel Washington Ruby Dee MoNique Terry McMilla 14367 330 National Organizations Issue Call to Action for Congress to Fully Fund Falls Prevention Programming in CDC Budget 14364 130 National Organizations Issue Call to Action for Congress to Fully Fund Falls Prevention Programming in CDC Budget 14364 230 National Organizations Issue Call to Action for Congress to Fully Fund Falls Prevention Programming in CDC Budget 14364 3JCI online early table of contents 3A March 13 2008 14362 1JCI online early table of contents 3A March 13 2008 14362 2JCI online early table of contents 3A March 13 2008 14362 3JCI online early table of contents 3A March 13 2008 14362 4JCI online early table of contents 3A March 13 2008 14362 5JCI online early table of contents 3A March 13 2008 14362 6JCI online early table of contents 3A March 13 2008 14362 7Lung Cancer Alliance Commends Leadership of MA State Senate 14360 1Lung Cancer Alliance Commends Leadership of MA State Senate 14360 2
...DGEWATER, N.J., July 05, 2007 /PRNewswire/ -- Resu...trolled, open-label, Phase,3 study showed that 77 ...ults taking PREZISTA(TM) (darunavir) 600 mg tablet...plus an optimized,background regimen (OBR) of anti...ad of <400 copies/mL at week 48, compared to 68,pe...
...rst prospective biomarker trial in non-small cell ...ire-FirstCall/ -- Response,Genetics, Inc. today an...ished in the July 1 issue of the Journal of Clinic...omarker,Excision-Repair Cross-Complementing 1 (ERC...ell lung cancer (NSCLC) predicts for,sensitivity t...
Other Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 2Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 3Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 4
The Libert Coronary Stent System introduces a new generation of lesion access and conformability. With exceptional flexibility, a low crossing profile, and the leading delivery catheter, the performa
..., and microplatesthat is the area of research in w...increasing force. Ergonomics (reduced weight and e...nel Research model was developed. This high-perfor... precise, and rapid processing of long series for ...
The Finnpipette Digital Multichannel, with it's streamlined design, makes even lighter work of routine laboratory tasks. The multichannel offers all these advanced features: Soft-touch tip ejection,
...mics, and value!, Comfortable feel and less hand ...er control while pipetting with smooth, light plun...long, lever tip ejector , Completely autoclavable ... the need for recalibration , Easy-to-read precisi...
Medicine Products: